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Running title: Fh1 is essential for HSC functions 
 
Abbreviations used: AML, acute myeloid leukaemia; FL, foetal liver; Fh1, fumarate hydratase; 
HSCs, haematopoietic stem cells; LICs, leukaemia-initiating cells; OCR, oxygen consumption rate; 
TCA cycle, tricarboxylic acid cycle 
 
Caption: 
Guitart et al. performed an in vivo genetic dissection of the Krebs cycle enzyme fumarate hydratase 
(Fh1) in the haematopoietic system. Their investigations revealed multifaceted functions of Fh1 in 
the regulation of haematopoietic stem cell biology and leukemic transformation. 
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ABSTRACT 
Strict regulation of stem cell metabolism is essential for tissue functions and tumour suppression. Here, 
we investigated the role of fumarate hydratase (Fh1), a key component of the mitochondrial 
tricarboxylic acid (TCA) cycle and cytosolic fumarate metabolism, in normal and leukaemic 
haematopoiesis. Haematopoiesis-specific Fh1 deletion (resulting in endogenous fumarate accumulation 
and a genetic TCA cycle block reflected by decreased maximal mitochondrial respiration) caused lethal 
foetal liver haematopoietic defects and haematopoietic stem cell (HSC) failure.  Re-expression of extra-
mitochondrial Fh1 (which normalised fumarate levels but not maximal mitochondrial respiration) 
rescued these phenotypes, indicating the causal role of cellular fumarate accumulation. However, HSCs 
lacking mitochondrial Fh1 (which had normal fumarate levels but defective maximal mitochondrial 
respiration) failed to self-renew and displayed lymphoid differentiation defects. In contrast, leukaemia-
initiating cells lacking mitochondrial Fh1 efficiently propagated Meis1/Hoxa9-driven leukaemia. Thus 
we identify novel roles for fumarate metabolism in HSC maintenance and haematopoietic 
differentiation, and reveal a differential requirement for mitochondrial Fh1 in normal haematopoiesis 
and leukaemia propagation. 
 
 
 
 
 
 
 
 
 
 
 
4 
INTRODUCTION 
Successful clinical application of haematopoietic stem cells (HSCs) is critically dependent on their 
ability to give long-term multilineage haematopoietic reconstitution (Weissman and Shizuru, 2008). 
Multiple studies have revealed the paradigmatic transcription factors driving HSC self-renewal and 
differentiation to sustain multilineage haematopoiesis (Gottgens, 2015). Emerging evidence 
indicates that strict control of HSC metabolism is also essential for their life-long functions 
(Manesia et al., 2015; Suda et al., 2011), but the key metabolic regulators that ensure stem cell 
integrity remain elusive. Although highly proliferative foetal liver (FL) HSCs utilise oxygen 
dependent pathways for energy generation (Manesia et al., 2015; Suda et al., 2011), adult HSCs are 
known to suppress the flux of glycolytic metabolites into the mitochondrial TCA cycle and heavily 
rely on glycolysis to maintain their quiescent state (Simsek et al., 2010; Takubo et al., 2013; Wang 
et al., 2014). While pharmacological inhibition of glycolytic flux into the TCA cycle enhances HSC 
activity upon transplantation (Takubo et al., 2013), severe block of glycolysis (i.e. Ldha deletion) 
and a consequent elevated mitochondrial respiration abolishes HSC maintenance (Wang et al., 
2014). The switch from glycolysis to mitochondrial oxidative metabolism is essential for adult HSC 
differentiation rather than maintenance of their self-renewing pool (Yu et al., 2013). Leukaemia-
initiating cells (LICs) are even more dependent on glycolysis than normal HSCs (Wang et al., 
2014). Partial or severe block in glycolysis (elicited by deletion of Pkm2 or Ldha, respectively) and 
a metabolic shift to mitochondrial respiration efficiently suppress the development and maintenance 
of LICs (Lagadinou et al., 2013; Wang et al., 2014). Thus the maintenance of adult self-renewing 
HSCs and LICs appears to critically depend on glycolysis rather than the mitochondrial TCA, 
which is thought to be less important for this process. However, thus far, the requirement for any of 
the TCA enzymes in FL and adult HSC and LIC maintenance has not been investigated.  
 
Genetic evidence in humans indicates that rare recessive mutations in the FH gene encoding a TCA 
enzyme fumarate hydratase result in severe developmental abnormalities, including haematopoietic 
defects (Bourgeron et al., 1994). Consistent with this, we also found that monozygous twins with 
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recessive FH mutations (Tregoning et al., 2013) display leukopenia and neutropenia (Table S1), 
thus suggesting a role for FH in the regulation of haematopoiesis. Mitochondrial and cytosolic 
fumarate hydratase enzyme isoforms, both encoded by the same gene (called FH in humans and 
Fh1 in mice) (Sass et al., 2001; Stein et al., 1994), catalyse hydration of fumarate to malate. While 
mitochondrial Fh1 is an integral part of the TCA cycle, cytosolic Fh1 metabolises fumarate 
generated during arginine synthesis, the urea cycle, and the purine nucleotide cycle in the cytoplasm 
(Yang et al., 2013). Autosomal dominant mutations in FH are associated with hereditary 
leiomyomatosis and renal cell cancer indicating that FH functions as a tumour suppressor 
(Launonen et al., 2001; Tomlinson et al., 2002). Given that FH mutations have been associated with 
haematopoietic abnormalities and tumour formation, here we investigated the role of Fh1 in normal 
and malignant haematopoiesis. 
 
RESULTS  
Fh1 is required for foetal liver haematopoiesis 
Fh1 is uniformly expressed in mouse Lin–Sca-1+c-Kit+ (LSK) CD48−CD150+ HSCs, 
LSKCD48−CD150− multipotent progenitors (MPPs), primitive haematopoietic progenitor cells (i.e. 
LSKCD48+CD150− HPC-1 and LSKCD48+CD150+ HPC-2 populations) and Lin−Sca-1−c-Kit+ (LK) 
myeloid progenitors sorted both from FL (the major site of definitive haematopoiesis during 
development) of 14.5 dpc embryos and adult bone marrow (BM) (Fig. 1A). To determine the 
requirement for Fh1 in HSC maintenance and multilineage haematopoiesis, we conditionally 
deleted Fh1 specifically within the haematopoietic system shortly after the emergence of definitive 
HSCs using the Vav-iCre deleter strain (de Boer et al., 2003). We bred Fh1fl/fl mice (Pollard et al., 
2007) with Vav-iCre mice and found no viable Fh1fl/fl;Vav-iCre offspring (Table S2). Fh1fl/fl;Vav-
iCre embryos were recovered at 14.5 dpc at normal Mendelian ratios, suggesting foetal or perinatal 
lethality. FLs isolated from Fh1fl/fl;Vav-iCre embryos appeared abnormally small and pale 
indicating severe impairment in FL haematopoiesis (Fig. 1B). Fh1 loss from the haematopoietic 
system was confirmed by the absence of Fh1 transcripts (Fig. 1C) in CD45+ and c-Kit+ 
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haematopoietic cells from Fh1fl/fl;Vav-iCre FLs and absence of Fh1 protein in FL c-Kit+ cells from 
Fh1
fl/fl;Vav-iCre embryos (Fig. 1D). While Fh1fl/fl;Vav-iCre FLs had decreased numbers of 
haematopoietic cells due to reduced numbers of differentiated lineage+ (Lin+) cells, the numbers of 
primitive FL Lin− cells remained unchanged (Fig. 1E). Colony-forming cell (CFC) assays indicated 
the failure of Fh1-deficient FL cells to differentiate (Fig. 1F). Analyses of erythroid differentiation 
revealed a block of erythropoiesis resulting in severe anaemia (Fig. 1G). Fh1 is therefore essential 
for multilineage differentiation of FL stem and/or progenitor cells.  
 
Fh1 is essential for HSC maintenance 
Next, we asked whether Fh1 is required for the maintenance of the stem and progenitor cell 
compartments in FLs. FLs from Fh1fl/fl;Vav-iCre embryos had normal absolute numbers of LK 
myeloid progenitors (Fig. 1H) and LSK stem and primitive progenitor cells (Fig. 1I) but displayed 
an increase in total numbers of HSCs compared to control FLs (Fig. 1J). To test the repopulation 
capacity of Fh1-deficient HSCs, we transplanted 100 CD45.2+ HSCs sorted from 14.5 dpc FLs into 
lethally irradiated syngeneic CD45.1+/CD45.2+ recipients and found that Fh1-deficient HSCs failed 
to reconstitute short-term and long-term haematopoiesis (Fig. 1K-L). To test the possibility that 
Fh1-deficient FLs contain stem cell activity outside the immunophenotypically defined 
LSKCD48−CD150+ HSC compartment, we transplanted unfractionated FL cells from Fh1fl/fl;Vav-
iCre and control embryos into lethally irradiated recipient mice (together with support BM cells) 
and found that Fh1-deficient FL cells failed to repopulate the recipients (Fig. 1M). Thus Fh1 is 
dispensable for HSC survival and expansion in the FL but is critically required for HSC 
maintenance upon transplantation.  
 
To establish the requirement for Fh1 in adult HSC maintenance we generated Fh1fl/fl;Mx1-Cre mice 
in which efficient recombination is induced by treatment with poly(I)-poly(C) (pIpC) (Kuhn et al., 
1995). We mixed CD45.2+ BM cells from untreated Fh1fl/fl;Mx1-Cre, Fh1+/fl;Mx1-Cre or control 
mice with CD45.1+ BM cells, transplanted them into recipient mice and allowed for efficient 
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reconstitution (Fig. 1N). pIpC administration to the recipients of Fh1fl/fl;Mx1-Cre BM cells resulted 
in a progressive decline of donor-derived CD45.2+ cell chimerism in PB (Fig. 1N) and a complete 
failure of Fh1-deficient cells to contribute to primitive and mature haematopoietic compartments of 
the recipients (Fig. 1O). Therefore, Fh1 is critical for the maintenance of both FL and adult HSCs.  
 
Fh1 deficiency results in cellular fumarate accumulation and decreased maximal 
mitochondrial respiration  
We next investigated the biochemical consequences of Fh1 deletion in primitive haematopoietic 
cells. To investigate how Fh1 loss affects the oxidative phosphorylation capacity of primitive FL c-
Kit+ haematopoietic cells, we measured oxygen consumption rate (OCR) under basal conditions and 
in response to sequential treatment with oligomycin (ATPase inhibitor), FCCP (mitochondrial 
uncoupler), and a concomitant treatment with rotenone and antimycin A (complex I and III 
inhibitors, respectively). The basal OCR was not affected in Fh1-deficient FL c-Kit+ cells, 
suggesting that the majority of mitochondrial NADH required for oxygen consumption in these 
cells originates from TCA-independent sources. However, the maximal OCR (after treatment with 
FCCP), which reflects maximal mitochondrial respiration, was profoundly decreased in Fh1-
deficient cells (Fig. 2A) (but not in Fh1+/fl;Vav-iCre cells; data not shown), indicating that Fh1 
deficiency may result in a compromised capacity to meet increased energy demands associated with 
metabolic stress or long-term survival (Choi et al., 2009; Ferrick et al., 2008; Keuper et al., 2014; 
van der Windt et al., 2012; Yadava and Nicholls, 2007). We also found that primitive Fh1-deficient 
FL haematopoietic cells failed to maintain ATP synthesis upon galactose-mediated inhibition of 
glycolysis (Fig. 2B, left panel), consistent with an increased reliance on glycolysis for ATP 
production. Furthermore, Fh1-deficient c-Kit+ cells had increased expression of glucose transporters 
(Glut1 and Glut3) and key glycolytic enzymes Hk2 and Pfkp, and displayed increased extracellular 
acidification rate (ECAR), indicative of enhanced glycolysis (Fig. 2C-D). Thus Fh1 deficiency 
results in an increase in glycolytic flux and impaired maximal mitochondrial respiration.  
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To determine the impact of Fh1 deletion on fumarate levels we performed mass spectrometry 
analyses. Fh1-deficient FL c-Kit+ cells accumulated high levels of endogenous cellular fumarate 
(Fig. 2E), consistent with previous observations in non-haematopoietic tissues harbouring Fh1 
mutation (Adam et al., 2013). Under the conditions of elevated fumarate, argininosuccinate is 
generated from arginine and fumarate by the reversed activity of the urea cycle enzyme 
argininosuccinate lyase (Zheng et al., 2013). We found that argininosuccinate is produced at high 
levels in Fh1-deficient c-Kit+ cells (Fig. 2F). Furthermore, fumarate, when accumulated at high 
levels, modifies cysteine residues in many proteins, forming S-(2-succinyl)-cysteine (2SC) (Adam 
et al., 2011; Alderson et al., 2006; Bardella et al., 2011; Ternette et al., 2013). Fh1-deficient c-Kit+ 
cells exhibited high immunoreactivity for 2SC (Fig. 2G). Thus primitive haematopoietic cells 
lacking Fh1 have compromised maximal mitochondrial respiration, display increased glycolysis, 
fail to maintain normal ATP production upon inhibition of glycolysis, and accumulate high levels of 
fumarate resulting in excessive protein succination.  
 
Efficient fumarate metabolism is essential for HSC maintenance and multilineage 
haematopoiesis 
Mechanistically, the phenotypes observed upon Fh1 deletion could result from the genetic block in 
the TCA cycle or the accumulation of cellular fumarate (Adam et al., 2011; Pollard et al., 2007). To 
differentiate between these two mechanisms we employed mice ubiquitously expressing a human 
cytoplasmic isoform of FH (FHCyt, which lacks the mitochondrial targeting sequence and therefore 
is excluded from the mitochondria) (Adam et al., 2013). FHCyt does not restore defects in 
mitochondrial oxidative metabolism but normalises levels of total cellular fumarate (Adam et al., 
2013; O'Flaherty et al., 2010). While primitive haematopoietic cells from FLs of Fh1fl/fl;FHCyt;Vav-
iCre embryos had normal mitochondrial membrane potential (data not shown) they displayed 
defective maximal respiration (Fig. 2A) and impaired compensatory mitochondrial ATP production 
upon inhibition of glycolysis (Fig. 2B, right panel), as well as an increase in ECAR  (Fig. 2D) 
similar to Fh1fl/fl;Vav-iCre FL cells. Furthermore, primitive Fh1fl/fl;FHCyt;Vav-iCre FL cells had 
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significantly reduced levels of cellular fumarate (Fig. 2E) and argininosuccinate (Fig. 2F), and 
undetectable immunoreactivity to 2SC (Fig. 2G), indicating that the biochemical consequences of 
fumarate accumulation were largely abolished by the FHCyt transgene expression. Although FHCyt 
transgene decreased overall cellular levels of fumarate, argininosuccinate and succinated proteins, 
we cannot exclude the possibility that fumarate is elevated in mitochondria and contributes to the 
impairment of mitochondrial function in the absence of mitochondrial Fh1. Collectively, while cells 
from Fh1fl/fl;FHCyt;Vav-iCre FL displayed impaired maximal respiration, they had cellular fumarate 
levels comparable to control cells.  
 
Notably, Fh1fl/fl;FHCyt;Vav-iCre mice were born at normal Mendelian ratios (Table S3) and matured 
to adulthood without any obvious defects. BM cells from adult Fh1fl/fl;FHCyt;Vav-iCre mice 
efficiently generated myeloid colonies (Fig. 2H), had normal BM cellularity (Fig. 2I), and displayed 
multilineage haematopoiesis (Fig. 2J-K), despite reduced numbers of B cells (Fig. 2K). 
Furthermore, they had unaffected numbers of LK myeloid progenitor cells (Fig. 2L), and increased 
numbers of LSK cells (Fig. 2M) and HSCs (Fig. 2N). Therefore, it is critical that HSCs and/or 
primitive progenitor cells efficiently metabolise fumarate to sustain haematopoietic differentiation. 
Finally, HSCs that acquire mitochondrial Fh1 deficiency (which abolishes maximal mitochondrial 
respiration) shortly after their emergence manage to survive, expand in the FL, colonise the BM and 
sustain steady-state multilineage haematopoiesis, implying that mitochondrial Fh1 is largely 
dispensable for these processes.  
 
Mitochondrial Fh1 deficiency compromises HSC self-renewal  
To stringently test the long-term self-renewal capacity of HSCs lacking mitochondrial Fh1 we 
performed serial transplantation assays. We transplanted 100 HSCs from FLs of Fh1fl/fl;FHCyt;Vav-
iCre, Fh1fl/fl;Vav-iCre and control 14.5 dpc embryos together with 200,000 support BM cells. 
While Fh1fl/fl;Vav-iCre HSCs failed to repopulate the recipients, Fh1fl/fl;FHCyt;Vav-iCre HSCs 
contributed to primitive and more mature haematopoietic compartments of the recipient mice (Fig 
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3A). Primary recipients of Fh1fl/fl;FHCyt;Vav-iCre HSCs displayed efficient myeloid lineage 
reconstitution while B- and T-lymphoid lineage reconstitution was less robust (Fig. 3B), suggesting 
that mitochondrial Fh1 is required for lymphoid cell differentiation or survival. We next sorted BM 
LSK cells from the primary recipients and re-transplanted them into secondary recipients. 
Fh1
fl/fl
;FH
Cyt
;Vav-iCre HSCs failed to contribute to the BM haematopoietic compartments of the 
recipients 20 weeks after transplantation (Fig. 3C). Therefore, HSCs lacking mitochondrial Fh1 
display progressive loss of self-renewal potential upon serial transplantation. 
 
Haematopoietic defects upon Fh1 deletion are not caused by oxidative stress or the activation 
of Nrf2-dependent pathways 
Since elevated cellular fumarate is a major cause of haematopoietic defects in Fh1fl/fl;Vav-iCre FLs, 
we next explored potential mechanisms through which fumarate impairs FL haematopoiesis. In 
non-haematopoietic tissues, fumarate succinates cysteine residues of biologically active molecules 
(including GSH (Sullivan et al., 2013; Zheng et al., 2015)) and numerous proteins (Adam et al., 
2011; Ternette et al., 2013). Elevated fumarate causes oxidative stress by succinating glutathione 
(GSH) and thus generating succinicGSH and depleting the GSH pool (Sullivan et al., 2013; Zheng 
et al., 2015). We found that reactive oxygen species (ROS) were modestly increased in Fh1fl/fl;Vav-
iCre FL c-Kit+ cells compared to control cells (Fig. 4A). The quantity of succinicGSH was elevated 
in Fh1fl/fl;Vav-iCre FL c-Kit+ cells (Fig. 4B) but succinicGSH constituted only approximately 1.5% 
of the total pool of glutathione species (Fig. 4C). Furthermore, we found that administration of the 
antioxidant N-acetyl cysteine (NAC) to timed-mated pregnant females did not rescue the reduced 
FL cellularity (data not shown), and failed to reverse decreased numbers of Lin+ FL cells (Fig. 4D). 
Finally, HSCs sorted from NAC-treated Fh1fl/fl;Vav-iCre FLs failed to reconstitute haematopoiesis 
in NAC-treated recipient mice (Fig. 4E). Therefore, oxidative stress due to GSH depletion does not 
cause haematopoietic defects resulting from fumarate accumulation. 
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Loss of Fh1 in renal cysts is associated with upregulation of Nrf2-mediated antioxidant response 
pathway due to fumarate-mediated succination of Keap1, which normally promotes Nrf2 
degradation (Adam et al., 2011). However, the analyses of global gene expression profiling of FL 
Lin−c-Kit+ primitive haematopoietic cells from 14.5 dpc Fh1fl/fl;Vav-iCre and control embryos 
revealed no significant enrichment for Nrf2 signature (Fig. 4F). Thus, the activation of the Nrf2-
dependent pathways is not responsible for defective haematopoiesis in Fh1fl/fl;Vav-iCre FLs.  
 
Fh1 deficiency in primitive haematopoietic cells has no impact on the Hif-1-dependent 
pathways and does not affect global 5-hydroxymethylcytosine levels  
Fumarate is known to competitively inhibit 2-oxoglutarate (2OG)-dependent oxygenases including 
Hif prolyl hydroxylase Phd2 resulting in stabilization of Hif-1α (Adam et al., 2011). Given that 
Phd2 deletion and stabilization of Hif-1α results in HSC defects (Singh et al., 2013; Takubo et al., 
2010), we asked whether elevated fumarate increases the Hif-1α protein levels upon Fh1 deletion in 
primitive haematopoietic cells. We found that Hif-1α protein was undetectable in Fh1fl/fl;Vav-iCre 
and control FL c-Kit+ cells (Fig. 4G), and additional deletion of Hif-1α in Fh1-deficient embryos 
failed to rescue embryonic lethality (data not shown), restore total FL cellularity, reverse decreased 
FL Lin+ cell numbers or normalise elevated numbers of FL HSCs (Fig. 4H). Thus Hif-1α is not 
involved in generating haematopoietic defects in Fh1fl/fl;Vav-iCre FLs. Given that fumarate can 
inhibit the Tet family of 5-methylcytosine hydroxylases (Xiao et al., 2012), we measured the levels 
of 5-hydroxymethylcytosine (5hmC) in Fh1fl/fl;Vav-iCre and control c-Kit+ cells and did not find 
any differences (data not shown), suggesting that fumarate-mediated Tet inhibition does not play a 
major role in generating haematopoietic defects in Fh1fl/fl;Vav-iCre FLs.  
 
Fh1 deletion results in increased histone H3 trimethylation in primitive haematopoietic cells 
Emerging evidence indicates that 2OG-dependent JmjC domain-containing histone demethylases 
(KDMs) play important roles in HSC biology and haematopoiesis (Andricovich et al., 2016; 
Stewart et al., 2015). Given that fumarate inhibits enzymatic activity of KDMs (Xiao et al., 2012), 
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we examined the abundance of H3K4me3, H3K9me3, H3K27me3 and H3K36me3 in nuclear 
extracts from FL c-Kit+ cells isolated from 14.5 dpc Fh1fl/fl;Vav-iCre and control embryos. Western 
blot analyses revealed an increase in levels of H3K9me3, H3K27me3 and H3K36me3 but not 
H3K4me3 in Fh1-deficient cells (Fig. 4I-J). While these data suggest that Fh1 deficiency results in 
enhanced trimethylation of H3, the identity of KDMs that are inhibited by fumarate, and the causal 
roles for increased H3 trimethylation in mediating HSC and haematopoietic defects upon Fh1 
deletion remain to be elucidated.  
 
Fh1 deletion promotes a gene expression signature that facilitates haematopoietic defects 
In order to understand the molecular signatures associated with Fh1 deficiency we performed gene 
expression profiling of FL Lin−c-Kit+ primitive haematopoietic cells from Fh1fl/fl;Vav-iCre and 
control embryos. We found that genes upregulated in Fh1-deficient cells are highly enriched in 
categories related to apoptosis in response to endoplasmic reticulum (ER) stress, protein metabolic 
process/protein translation and unfolded protein response (Fig. 4K-L). Downregulated genes are 
enriched in pathways related to haem biosynthesis, erythroid and myeloid function, and the cell 
cycle (Fig. 4K). Although further detailed work will be needed to experimentally verify this, we 
propose that enhanced ER stress, unfolded protein response and increased protein translation (which 
are known to contribute to HSC depletion and haematopoietic failure (Miharada et al., 2014; Signer 
et al., 2014; van Galen et al., 2014)) may be responsible for haematopoietic defects upon Fh1 
deletion. 
 
Fh1 deficiency abolishes leukaemic transformation and LIC functions 
While FH is a tumour suppressor (i.e. FH mutations result in hereditary leiomyomatosis and renal-
cell cancer) and fumarate is proposed to function as an oncometabolite (Yang et al., 2013), the role 
of FH in leukaemic transformation remains unknown. Given that human AML cells express high 
levels of FH protein (Elo et al., 2014; Lopez-Pedrera et al., 2006) and enzymatic activity of FH is 
increased in AML samples compared to cells from normal controls (Tanaka and Valentine, 1961), 
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we next investigated the role for Fh1 in leukaemic transformation. We employed a mouse model of 
AML in which the development and maintenance of leukaemia-initiating cells (LICs) is driven by 
Meis1 and Hoxa9 oncogenes (Vukovic et al., 2015; Wang et al., 2010). Meis1 and Hoxa9 are 
frequently overexpressed in several human AML subtypes (Drabkin et al., 2002; Lawrence et al., 
1999) and their overexpression in mouse haematopoietic stem and progenitor cells generates self-
renewing LICs (Kroon et al., 1998). In the Meis1/Hoxa9 model employed here, the FL LSK or c-
Kit+ cell populations are transduced with retroviruses expressing Meis1 and Hoxa9, and are serially 
re-plated, generating a pre-leukaemic cell population which upon transplantation to primary 
recipients, develops into LICs causing AML. LICs are defined by their capacity to propagate AML 
with short latency in secondary recipients (Somervaille and Cleary, 2006; Vukovic et al., 2015; 
Yeung et al., 2010). We found that Fh1fl/fl;Vav-iCre FL stem and progenitor cells transduced with 
Meis1/Hoxa9 (Fig. 5A) failed to generate colonies in methylcellulose (Fig. 5B). To corroborate 
these findings, we used retroviruses expressing MLL fusions which are frequently found in acute 
monoblastic leukemia (AML M5) and are associated with an unfavourable prognosis in AML, 
namely MLL-ENL (fusion oncogene resulting from t(11;19)) and MLL-AF9 (resulting from t(9;11)) 
(Krivtsov and Armstrong, 2007; Lavallee et al., 2015). We also used AML1-ETO9a, a splice variant 
of AML1-ETO that is frequently expressed in t(8;21) patients with AML M2 and its high 
expression correlates with poor AML prognosis (Jiao et al., 2009). MLL fusions and AML1-ETO9a 
drive leukaemogenesis through distinct pathways and are frequently used to transform murine 
haematopoietic cells (Smith et al., 2011; Velasco-Hernandez et al., 2014; Zuber et al., 2009). We 
found that Fh1-deficient cells transduced with MLL-ENL, MLL-AF9 and AML1-ETO9a were unable 
to generate colonies (Fig. 5B), indicating the requirement for Fh1 in in vitro transformation. We 
next determined the impact of Fh1 deletion on the colony formation capacity of pre-leukaemic cells 
(Fig. 5C). We transduced Fh1+/+ and Fh1fl/fl FL LSK cells with Meis1 and Hoxa9 retroviruses and 
following three rounds of re-plating we infected the transformed cells with Cre lentiviruses. Fh1fl/fl 
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cells expressing Cre failed to generate colonies in CFC assays (Fig. 5D). Thus Fh1 deletion inhibits 
the generation of pre-leukaemic cells and abolishes their clonogenic capacity.  
 
To determine the requirement for Fh1 in LICs, LSK cells from Fh1+/+ and Fh1fl/fl FLs were 
transduced with Meis1 and Hoxa9 retroviruses, and transplanted into primary recipients (Fig. 5C). 
LICs isolated from leukaemic primary recipient mice were infected with Cre lentivirus and plated 
into methylcellulose. We found that Fh1-deficient LICs were unable to generate colonies (Fig. 5E). 
We next investigated the requirement for FH in human established leukaemic cells by knocking 
down the expression of FH in human AML (M5) THP-1 cells harbouring MLL-AF9 translocation. 
We generated lentiviruses expressing 3 independent short-hairpins (i.e. FH shRNA 1-3) targeting 
FH, and scrambled shRNA sequence. Based on knockdown efficiency (Fig. 5F-G) we selected FH 
shRNA1 and FH shRNA3 for further experiments. FH knockdown increased apoptosis of THP-1 
cells (Fig. 5H) and decreased their ability to form colonies (Fig. 5I). Therefore, Fh1 is required for 
survival of both mouse LICs and human established leukaemic cells. Finally, we conclude that the 
tumour suppressor functions of FH are tissue-specific and do not extend to haematopoietic cells.  
 
Mitochondrial Fh1 is necessary for AML development but is not required for disease 
maintenance  
We next investigated the impact of mitochondrial Fh1 deficiency on in vitro transformation and 
development and maintenance of LICs (Fig. 6A-C). FL Fh1fl/fl;FHCyt;Vav-iCre cells transduced 
with Meis1/Hoxa9 retroviruses had normal serial re-plating capacity (Fig. 6B), and the established 
pre-leukaemic cells had normal proliferative capacity and cell-cycle status (data not shown). Thus 
elevated fumarate is largely responsible for the inability of Fh1fl/fl;Vav-iCre stem and progenitor 
cells to undergo in vitro transformation. To establish the requirement for mitochondrial Fh1 in 
AML development in vivo, we transplanted control (Fh1fl/fl), control;FHCyt and Fh1fl/fl;FHCyt;Vav-
iCre Meis1/Hoxa9-transduced pre-leukaemic cells into sub-lethally irradiated recipient mice (Fig. 
6A). We found that the percentage of recipients of Fh1fl/fl;FHCyt;Vav-iCre cells that developed 
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terminal AML was significantly reduced (and the disease latency was extended) compared to 
recipients of control and control;FHCyt cells (Fig. 6C). Finally, OCR measurement in LICs sorted 
from those recipients of Fh1fl/fl;FHCyt;Vav-iCre cells that succumbed to AML revealed that 
Fh1
fl/fl
;FH
Cyt
;Vav-iCre LICs had defective maximal mitochondrial respiration compared to control 
and control;FHCyt LICs (data not shown). Thus mitochondrial Fh1 is required for efficient 
generation of LICs and AML development in a Meis1/Hoxa9-driven model of leukaemogenesis.  
 
Given that mitochondrial Fh1 was important for leukaemia initiation, we next asked whether 
inducible deletion of mitochondrial Fh1 from leukaemic cells impacts on leukaemia propagation 
and LIC maintenance (Fig. 6D-J). We transduced control and Fh1fl/fl;FHCyt;Mx1-Cre FL LSK cells 
with Meis1/Hoxa9 retroviruses and following serial re-plating the resultant pre-leukaemic cells 
were transplanted into primary recipient mice (Fig. 6D). Upon disease diagnosis (i.e. 20% of 
CD45.2+ leukaemic cells in the PB), the mice received 8 pIpC doses (Fig. 6D). Recipients of both 
control and Fh1fl/fl;FHCyt;Mx1-Cre cells equally succumbed to terminal AML (Fig. 6E-F). After 
confirming efficient Fh1 deletion (Fig. 6G) and defective maximal respiration (Fig. 6H), we 
isolated LICs from the BM of leukaemic primary recipient mice and transplanted them into 
secondary recipients. We found that LICs lacking mitochondrial Fh1 and control LICs equally 
efficiently caused leukaemia in secondary recipients (Fig. 6I-J). Thus mitochondrial Fh1 is 
necessary for efficient LIC generation but is not required for their ability to efficiently propagate 
Meis1/Hoxa9-driven leukaemia.  
 
DISCUSSION 
By performing genetic dissection of multifaceted functions of the key metabolic gene Fh1 we have 
uncovered a previously unknown requirement for fumarate metabolism in the haematopoietic 
system. We conclude that efficient utilization of intracellular fumarate is required to prevent its 
potentially toxic effects and is central to the integrity of HSCs and haematopoietic differentiation. 
Furthermore, although fumarate promotes oncogenesis in the kidney (Yang et al., 2013), it has the 
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opposite effect in the haematopoietic system, i.e. it inhibits leukaemic transformation. Our data 
indicating a detrimental impact of fumarate on haematopoiesis, taken together with fumarate’s 
functions as an oncometabolite in non-haematopoietic tumours (Yang et al., 2013), or a protective 
role within the myocardium (Ashrafian et al., 2012), highlight distinct functions of fumarate in 
different tissues.  
 
Elevated fumarate within the haematopoietic system is likely to perturb multiple biochemical 
mechanisms. Fumarate is known to inhibit 2OG-dependent oxygenases, including HIF-hydroxylase 
Phd2 (Hewitson et al., 2007), the Tet enzymes and KDMs (Xiao et al., 2012) and as a consequence 
tumour cells with FH mutations have increased HIF-1α stability and display a hypermethylator 
phenotype (Castro-Vega et al., 2014; Isaacs et al., 2005; Letouze et al., 2013; Pollard et al., 2007). 
We found that haematopoietic defects resulting from elevated fumarate are most likely generated 
through the Hif-1-independent and Tet-independent mechanisms. However, consistent with the 
ability of fumarate to inhibit KDMs, we found that levels of H3K9me3, H3K27me3 and H3K36me3 
were elevated in primitive haematopoietic cells lacking Fh1. Although detailed underlying 
mechanisms remain to be elucidated, we propose that elevated fumarate may cause the observed 
phenotypes by inhibiting these KDMs that are essential for normal haematopoiesis and HSC 
functions, including KDM5B (Stewart et al., 2015) and KDM2B (Andricovich et al., 2016).  
 
Fumarate is also known to cause succination of cysteine residues of numerous proteins (e.g. Keap1, 
which normally promotes Nrf2 degradation (Adam et al., 2011; Ternette et al., 2013)) or GSH 
(Sullivan et al., 2013; Zheng et al., 2015). However, our data indicated that haematopoietic defects 
upon Fh1 deletion are unlikely to be mediated by Nrf2 activation or GSH depletion. Given our 
findings that Fh1-deficient cells have increased signatures of ER stress and unfolded protein 
response, it will be of high interest to determine whether increased global protein succination in 
Fh1-deficient cells results in protein misfolding in HSCs, leading to the activation of unfolded 
protein response which is detrimental to HSC integrity (van Galen et al., 2014).  
 
17 
Fh1 deletion with the simultaneous re-expression of cytosolic FH allowed us to investigate the 
genetic requirement for mitochondrial Fh1 in long-term HSC functions. Our serial transplantation 
assays revealed that mitochondrial Fh1 was essential for HSC self-renewal, indicating a key role for 
an intact TCA cycle in HSC maintenance. Intriguingly, while mitochondrial Fh1 deficiency did not 
affect myeloid output under steady-state conditions and upon transplantation, the lack of 
mitochondrial Fh1 had an impact on the lymphoid output. These data imply differential 
requirements for the intact TCA cycle in lineage commitment and/or differentiation of primitive 
haematopoietic cells, meriting further investigations.  
 
Both self-renewing HSCs and LICs are thought to rely heavily on glycolysis while they suppress 
the TCA cycle (Simsek et al., 2010; Wang et al., 2014). We utilised the genetic mitochondrial Fh1 
deficiency to examine the differential requirement for mitochondrial Fh1 in long-term HSC self-
renewal and the development and maintenance of LICs. We conclude that self-renewing HSCs 
critically require intact mitochondrial Fh1 and the capacity for maximal mitochondrial respiration to 
maintain their pool. However, while mitochondrial Fh1 was necessary for LIC development, it had 
no impact on maintenance of LICs. Thus we reveal a differential requirement for the mitochondrial 
TCA enzyme Fh1 in normal haematopoiesis and Meis1/Hoxa9-driven leukaemia propagation. The 
discovery of mechanisms underlying different metabolic requirements in HSCs and LICs represent 
a key area for future investigations.  
MATERIALS AND METHODS 
Mice 
All mice were on the C57BL/6 genetic background. Fh1fl/fl (Pollard et al., 2007), Hif-1αfl/fl (Ryan et 
al., 2000; Vukovic et al., 2016) and V5-FHCyt (for simplicity referred to as FHCyt) (Adam et al., 
2013) were described previously. Vav-iCre and Mx1-Cre were purchased from the Jackson 
Laboratory. All transgenic and knockout mice were CD45.2+. Congenic recipient mice were 
18 
CD45.1+/CD45.2+. All experiments on animals were performed under UK Home Office 
authorisation. 
 
Flow cytometry 
All BM and FL samples were stained and analysed as described previously (Guitart et al., 2013; 
Kranc et al., 2009; Mortensen et al., 2011; Vukovic et al., 2016). BM cells were obtained by 
crushing tibias and femurs with a pestle and mortar. FL cells were obtained by mashing the tissue 
through a 70µm strainer. Single cell suspensions from BM, FL or PB were incubated with Fc block 
and then stained with antibodies. For HSC analyses, following incubation with Fc block, 
unfractionated FL or BM cell suspensions were stained with lineage markers containing biotin-
conjugated anti-CD4, anti-CD5, anti-CD8a, anti-CD11b (not used in FL analyses), anti-B220, anti-
Gr-1 and anti-Ter119 antibodies together with APC-conjugated anti-c-Kit, APC/Cy7-conjugated 
anti-Sca-1, PE-conjugated anti-CD48 and PE-Cy7-conjugated anti-CD150 antibodies. Biotin-
conjugated antibodies were then stained with Pacific Blue-conjugated or PerCP-conjugated 
streptavidin. To distinguish CD45.2+-donor derived HSCs in recipient mice, FITC-conjugated anti-
CD45.1 and Pacific Blue-conjugated anti-CD45.2 antibodies were included in the antibody cocktail 
described above. The multilineage reconstitution of recipient mice was determined by staining the 
BM or PB cell suspensions of the recipient mice with FITC-conjugated anti-CD45.1, Pacific Blue-
conjugated anti-CD45.2, PE-conjugated anti-CD4 and-CD8a, PE/Cy7-conjugated anti-Gr-1, APC-
conjugated anti-CD11b, APC-Cy7-conjugated anti-CD19 and anti-B220). In all analyses, 7-AAD or 
DAPI were used for dead cell exclusion.  
 
Flow cytometry analyses were performed using a LSRFortessa (BD). Cell sorting was performed on 
a FACSAria Fusion (BD).  
 
Colony forming cells (CFC) assays 
CFC assays were performed using MethoCultTM M3434 (STEMCELL Technologies). Two 
replicates were used per group in each experiment. Colonies were tallied at day 10.  
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Leukaemic transformation  
LSK cells were sorted from FLs of 14.5 dpc embryos following c-Kit (CD117) enrichment using 
MACS columns (Miltenyi Biotec). 10,000 LSK cells were simultaneously transduced with MSCV-
Meis1a-puro and MSCV-Hoxa9-neo retroviruses and subsequently subjected to three rounds of 
CFC assays in MethoCultTM M3231 (STEMCELL Technologies) supplemented with 20ng/ml SCF, 
10ng/ml IL-3, 10ng/ml IL-6 and 10ng/ml GM-SCF. Colonies were counted 6-7 days after plating, 
and 2,500 cells were re-plated. Similarly, 200,000 FL c-Kit+ cells were transduced with MSCV-
AML1-ETO9a-neo, MSCV-MLL-AF9-neo or MSCV-MLL-ENL-neo and subsequently plated into 
methylcellulose. 
 
Transplantation assays 
Lethal irradiation of CD45.1+/CD45.2+ recipient mice was achieved using a split dose of 11 Gy 
(two doses of 5.5 Gy administered at least 4 hours apart) at an average rate of 0.58 Gy/min using a 
Cesium 137 GammaCell 40 irradiator. For sub-lethal irradiation, the recipient mice received a split 
dose of 7 Gy (two doses of 3.5 Gy, at least 4 hours apart).  
 
For primary transplantations 100 HSCs (LSKCD48-CD150+CD45.2+) sorted from FLs of 14.5 dpc 
embryos or 200,000 unfractionated FL cells were mixed with 200,000 support CD45.1+ BM cells 
and injected into lethally irradiated (11 Gy delivered in a split dose) CD45.1+/CD45.2+ recipient 
mice. For secondary transplantations 2,000 CD45.2+ LSK cells sorted from BM of primary 
recipients were mixed with 200,000 support CD45.1+ wild-type BM cells and re-transplanted. For 
adult BM transplantations 500,000 CD45.2+ BM cells were mixed with 500,000 support CD45.1+ 
wild-type BM cells and injected into lethally irradiated CD45.1+/CD45.2+ recipient mice. All 
recipient mice were analysed 18-20 weeks post-transplantation, unless otherwise stated.  
 
For leukaemia induction, 100,000 Meis-1/Hoxa9-transduced c-Kit+ cells were transplanted into 
CD45.1+/CD45.2+ sub-lethally irradiated (7 Gy delivered in a split dose) recipient mice. The mice 
were monitored for AML development. For secondary transplantation, 10,000 LICs (CD45.2+c-Kit+ 
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cells) were sorted from BM of primary recipients and transplanted into secondary 
CD45.1+/CD45.2+ sub-lethally irradiated recipient mice. 
 
Inducible Mx1-Cre-mediated gene deletion 
Mice were injected intraperitoneally 6-8 times every alternate day with 300 µg pIpC (GE 
Healthcare) as previously described (Guitart et al., 2013; Kranc et al., 2009).  
 
Administration of N-acetylcysteine (NAC) 
Pregnant females received 30 mg/mL of NAC (Sigma-Aldrich) in drinking water (pH was adjusted 
to 7.2-7.4 with NaOH). For transplantation experiments, CD45.1+/CD45.2+ recipient mice were 
treated with 30 mg/mL NAC in drinking water 7 days prior to irradiation, and remained under NAC 
treatment for the duration of the experiment. The water bottle containing NAC was changed twice a 
week.  
 
Oxygen consumption assays 
Oxygen consumption rate (OCR) measurements were made using a Seahorse XF-24 analyser 
(Seahorse Bioscience) and the XF Cell Mito Stress Test Kit as previously described (Wang et al., 
2014). Briefly, c-Kit+ cells from FLs of 14.5 dpc embryos were plated in XF-24 microplates pre-
coated with cell-tak (BD) at 250,000 cells per well in XF Base Medium supplemented with 2 mM 
pyruvate and 10 mM glucose (pH 7.4). OCR was measured 3 times every 6 min for basal value and 
after each sequential addition of oligomycin (1µM), FCCP (1µM) and finally concomitant rotenone 
and antimycin A (1µM). 1µM FCCP was used as at this concentration FCCP elicited maximal fold 
increase in OCR (data not shown). Oxygen consumption measurements were normalised to cell 
counts performed before and after each assay. 
 
Metabolite detection by LC-MS 
Metabolites from c-Kit+ cells from FLs of 14.5 dpc embryos were extracted into 50% 
methanol/30% acetonitrile and measured as previously described (Adam et al., 2013).  
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Western blotting 
Protein extracted from FL c-Kit+ cells of 14.5 dpc embryos was subjected to a 10% SDS–PAGE 
then transferred onto a PVDF membrane and immunoblotted with anti-Fh1, anti-2-SC and anti-Hif-
1α as previously described (Adam et al., 2011; Bardella et al., 2012). Anti-H3K4me3 (07-473; 
Millipore), anti-H3K9me3 (ab8898; Abcam), anti-H3K27me3 (07-449; Millipore), anti-H3K36me3 
(ab9050; Abcam) were used to determine levels of trimethylated H3. Anti-actin (A5316; Sigma), 
anti-tubulin (2146S; Cell signalling) and anti-H3 (ab1791; Abcam) immunoblots were used as 
loading controls.  
 
RT-qPCR 
Gene expression analyses were performed as described previously (Guitart et al., 2013; Kranc et al., 
2009; Mortensen et al., 2011). Differences in input cDNA were normalised with Actb (beta actin) 
expression. 
 
ATP production  
10,000 c-Kit+ cells from FLs of 14.5 dpc embryos were cultured in DMEM supplemented with 
either 25mM glucose or 25mM galactose. At 0 and 24 hours after incubation the cells were lysed 
and ATP content was measured by luminescence using CellTiterGlo Assay (Promega).  
 
Measurement of mitochondrial membrane potential  
50,000 FL c-Kit+ cells from 14.5 dpc embryos were incubated for 15min at 37°C in 25nM TMRM 
(T-668, Life Technologies) and analysed using the LSRFortessa flow cytometer.  
 
Gene expression profiling and bioinformatics analyses 
RNA from sorted FL Lin−c-Kit+ cells was isolated by standard phenol/chloroform extraction. cDNA 
was synthesised from 50ng of total RNA using the Ambion WT Expression kit (Life Technologies). 
Labeled, fragmented cDNA (Affymetrix GeneChip® WT Terminal Labeling and Controls Kit) was 
hybridized to Mouse Gene 2.0 arrays for 16 hours at 45°C (at 60rpm) (Affymetrix GeneChip® 
Hybridization, Wash, and Stain Kit). Arrays were washed and stained using the Affymetrix Fluidics 
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Station 450, and scanned using the Hewlett-Packard GeneArray Scanner 3000 7G. The microarray 
gene expression data have been deposited in ArrayExpress (accession number E-MTAB-5425). 
 
For bioinformatics analyses, a total of 7 arrays (n = 3 Fh1fl/fl, n = 4 Fh1fl/fl;Vav-iCre) were QC 
(quality control) analysed using arrayQualityMetrics package in Bioconductor. Normalisation of the 
29638 features across all arrays was achieved using the robust multi-array average (RMA) 
expression measure. Pairwise group comparisons were undertaken using linear modelling (LIMMA 
package in Bioconductor). Subsequently, empirical Bayesian analysis was applied, including 
vertical (within a given comparison) p-value adjustment for multiple testing, which controls for 
false-discovery rate.  
 
Gene set enrichment analysis 
Gene expression differences were ranked by difference of log expression values, and this ranking 
was used to perform gene set enrichment analysis (GSEA) (Subramanian et al., 2005) on gene lists 
in the Molecular signatures database (MSigDB, version 5.2). The following datasets were used for 
analyses presented in Fig. 4: 1) Hallmark, unfolded protein response; 2) GO, Intrinsic apoptotic 
signalling pathway in response to endoplasmic reticulum stress; 3) Reactome, translation; and 4) 
NFE2L2.V2. 
 
shRNA-dedicated FH knockdown 
THP-1 cells were transduced with lentiviruses expressing shRNAs (shRNA1: TAATCCTGGT 
TTACTTCAGCG (TRCN0000052463), shRNA2: AAGGTATCATATTCTATCCGG 
(TRCN0000052464), shRNA3: TTTATTAACATGATCGTTGGG (TRCN0000052465) and 
shRNA Scr: TTCTCCGAACGTGTCACGTT; Dharmacon™RNAi Consortium). Transduced THP-
1 cells were grown in the presence of 5ug/mL puromycin. 
 
ROS analysis 
c-Kit+ cells were stained with 2.5nM CellROX (C10491, Life Technologies) based on the 
manufacturer’s protocol and analysed by FACS.  
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Statistical analyses           
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc.) P 
values were calculated using a two-tailed Mann–Whitney U test unless stated otherwise. Kaplan-
Meier survival curve statistics were determined using the Log-rank (Mantel Cox) test. 
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Figure Legends 
Figure 1. Haematopoiesis-specific Fh1 deletion results in severe haematopoietic defects and 
loss of HSC activity. (A) Relative levels of Fh1 mRNA (normalised to Actb) in HSCs, MPPs, 
HPC-1 and HPC-2 populations, LSK and LK cells sorted from 14.5 dpc FLs and BM of C57BL/6 
adult (8-10 week old) mice. Data are mean ± s.e.m. (n = 3). (B) FLs from 14.5 dpc Fh1fl/fl;Vav-iCre 
embryos are smaller and paler compared to Fh1+/fl;Vav-iCre and control embryos. (C) The absence 
of Fh1 transcripts in Fh1fl/fl;Vav-iCre FL CD45+ and c-Kit+ cells. Data are mean ± s.e.m. (control n 
= 3 and Fh1fl/fl;Vav-iCre n = 6). (D) Western blots for Fh1 and β-actin in FL c-Kit+ cells. (E) Total 
cellularity (the sum of Lin+ and Lin− cell numbers) in 14.5 dpc FLs of the indicated genotypes. Data 
are mean ± s.e.m. (control n = 17, Fh1+/fl;Vav-iCre n = 11, Fh1fl/fl;Vav-iCre n = 9). (F) CFC assay 
with FL cells. Data are mean ± s.e.m. (control n = 11, Fh1+/fl;Vav-iCre n = 8, Fh1fl/fl;Vav-iCre n = 
4). (G) Erythropoiesis in 14.5 dpc FLs. Arranged from least to most differentiated, Ter119−CD71−, 
Ter119–CD71+, Ter119+CD71+ and Ter119+CD71–. Data are mean ± s.e.m. (control n = 11, 
Fh1
+/fl;Vav-iCre n = 8, Fh1fl/fl;Vav-iCre n = 4). (H-J) Total number of LK cells (H), LSK cells (I) 
and HSCs (J) in 14.5 dpc FLs. Data are mean ± s.e.m. (control n = 17, Fh1+/fl;Vav-iCre n = 11, 
Fh1
fl/fl;Vav-iCre n = 9). (K-L) Percentage of donor-derived CD45.2+ cells in PB (K), and total BM 
and the BM LSK cell compartment (L) of the recipient mice transplanted with 100 FL HSCs. Data 
are mean ± s.e.m.; n = 5-8 recipients per genotype, at least 3 donors were used per genotype. (M) 
Percentage of CD45.2+ cells in PB after transplantation of 200,000 total FL cells.  Data are mean ± 
s.e.m.; n = 3-4 recipients per genotype, at least 3 donors were used per genotype. (N-O) Acute 
deletion of Fh1 from the adult haematopoietic system. 5x105 unfractionated CD45.2+ BM cells from 
untreated Fh1fl/fl (control), Fh1+/fl;Mx1-Cre and Fh1fl/fl;Mx1-Cre C57BL/6 (8-10 week old) mice 
were mixed with 5x105 CD45.1+ WT BM cells and transplanted into lethally irradiated  
CD45.1+/CD45.2+ recipients. 8 weeks after transplantation, the recipients received 6 doses of pIpC. 
(N) Percentage of donor-derived CD45.2+ cells in PB (n = 5-10 recipients per genotype; n = 2 
donors per genotype). (O) Percentage of CD45.2+ cells in the Lin+, Lin−, LK, LSK and HSC cell 
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compartments of the recipient mice 11 weeks after pIpC treatment. Data are mean ± s.e.m. (n = 7-8 
recipients per genotype). (C, E, F-G, and J-O) *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001 (Mann-Whitney U test). 
 
Figure 2. Cytosolic isoform of Fh1 restores normal steady-state haematopoiesis in Fh1fl/fl;Vav-
iCre mice. (A) OCR in FL c-Kit+ cells under basal conditions and following the sequential addition 
of oligomycin, FCCP, and rotenone and antimycin A. Data are mean ± s.e.m. (control n = 5, 
Fh1
fl/fl;Vav-iCre n = 3, control;FHCyt n = 10, Fh1fl/fl;FHCyt;Vav-iCre n =5). (B) OXPHOS-
dependent ATP production in galactose (Gal)-treated FL c-Kit+ Fh1fl/fl;Vav-iCre and 
Fh1
fl/fl;FHCyt;Vav-iCre cells. Control (n = 9), Fh1fl/fl;Vav-iCre (n = 9), control;FHCyt (n = 6), 
Fh1
fl/fl;FHCyt;Vav-iCre (n = 10). FL c-Kit+ cells were cultured in DMEM supplemented with either 
25 mM glucose (Glu) or 25 mM Gal. The graph shows the ratio of ATP produced in the presence of 
Gal (permissive for oxidative phosphorylation only) to ATP generated in the presence of Glu 
(permissive for both oxidative phosphorylation and glycolysis). Data are mean ± s.e.m. (control n = 
9, Fh1fl/fl;Vav-iCre n = 10, control;FHCyt n =6, Fh1fl/fl;FHCyt;Vav-iCre n = 9). (C) Relative 
expression (normalised to Actb) of genes involved in glycolysis in FL c-Kit+ cells. Data are mean ± 
s.e.m.; n = 4-5 per genotype. (D) ECAR under basal conditions in 14.5 dpc FL c-Kit+ cells. Data are 
mean ± s.e.m. (control n = 6, Fh1fl/fl;Vav-iCre n = 5, control;FHCyt n =10, Fh1fl/fl;FHCyt;Vav-iCre n 
= 4). (E) Fumarate and (F) argininosuccinate levels in FL c-Kit+ cells measured using LC-MS. Data 
are mean ± s.e.m. (control n = 6, Fh1fl/fl;Vav-iCre n = 4, control;FHCyt n = 6, Fh1fl/fl;FHCyt;Vav-
iCre n = 13). (G) 14.5 dpc FL cell extracts were immunoblotted with a polyclonal anti-2SC 
antibody. α-tubulin was used as a loading control. Data are representative of two independent 
experiments. (H) Colony forming unit (CFU) assays performed with BM cells from 8-10 week old 
mice of the indicated genotypes. CFU-erythroid and/or megakaryocyte (Red); CFU-granulocyte 
(G); CFU-monocyte/macrophage (M) CFU-granulocyte and monocyte/macrophage (GM); CFU-
mix, at least three of the following: G, E, M and Mk. Data are mean ± s.e.m. (n = 3-5 per genotype) 
and are representative of 3 independent experiments. (I) Total number of BM nucleated cells 
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obtained from 2 tibias and 2 femurs of 8-10 week old mice. Data are mean ± s.e.m. (n = 3-4 per 
genotype). (J-N) Total numbers of CD11b+Gr-1+ myeloid cells (J), CD19+B220+ B cells (K), LK 
cells (L), LSK cells (M), and HSCs (N) in 2 tibias and 2 femurs. Data are mean ± s.e.m. (n = 3-4 per 
genotype). (A-F, H, K, M-N) *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Mann-
Whitney U test).  
 
Figure 3. Mitochondrial Fh1 is essential for HSC self-renewal. 100 FL HSCs were transplanted 
into lethally irradiated 8-10 week old C57BL/6 CD45.1+/CD45.2+ recipient mice together with 
2x105 CD45.1+ syngeneic competitor BM cells. The primary recipients were analysed 20 weeks 
after transplantation. 2,000 CD45.2+LSK cells were sorted from their BM and transplanted into 
secondary recipients together with competitor BM cells. Secondary recipients were analysed 20 
weeks after transplantation. (A) Percentage of CD45.2+ cells in the Lin+, Lin−, LK, LSK and HSC 
compartments in the BM of primary recipients. Data are mean ± s.e.m.; n = 4-5 recipients per donor 
(B) Percentage of CD45.2+ cells in the monocyte, neutrophil, B cell and T cell compartments in the 
PB of primary recipients. Data are mean± s.e.m. (n = 4-5 recipients per donor). Number of donors 
used in (A) and (B): control n = 6, Fh1+/fl;Vav-iCre n = 2, Fh1fl/fl;Vav-iCre n = 2, control;FHCyt n = 
6, Fh1+/fl;FHCyt;Vav-iCre n = 3, Fh1fl/fl;FHCyt;Vav-iCre n = 3). (C) Percentage of CD45.2+ cells in 
the Lin+, Lin−, LK, LSK and HSC compartments in the BM of the secondary recipients. Data are 
mean ± s.e.m. n = 4-5 recipients per donor (number of donors: control n = 3, control;FHCyt n = 4, 
Fh1
+/fl;FHCyt;Vav-iCre n = 2 and Fh1fl/fl;FHCyt;Vav-iCre n = 3). (A-C) *, P < 0.05; **, P < 0.01 
(Mann-Whitney U test).  
 
Figure 4. Molecular consequences of Fh1 deletion in primitive haematopoietic cells. 
(A) Intracellular ROS in FL c-Kit+ cells. Data are the mean of mean fluorescence intensities ± 
s.e.m. (control n = 6 and Fh1fl/fl;Vav-iCre n = 3). (B-C) Glutathione species in 14.5 dpc FL c-Kit+ 
cells measured using LC-MS. (B) SuccinicGSH levels (arbitrary units) and (C) percentage of 
SuccinicGSH within the total glutathione species. Data are mean ± s.e.m. (control n = 6 and 
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Fh1
fl/fl;Vav-iCre n = 3). (D-E) Pregnant females were treated with NAC administered 7 days prior 
to the embryo harvest. (D) Lin+ cell numbers in 14.5 dpc FLs. Data are mean ± s.e.m. (control n = 
15, Fh1fl/fl;Vav-iCre n = 6, control + NAC n = 4 and Fh1fl/fl;Vav-iCre + NAC n = 4). (E) 600,000 
total FL cells of 14.5 dpc embryos from NAC-treated pregnant females, were transplanted into 
lethally irradiated CD45.1+/CD45.2+ recipient mice together with 200,000 CD45.1+ competitor BM 
cells. Recipients were continuously treated with NAC. Data represent percentage of donor-derived 
CD45.2+ cells in PB 3 weeks post-transplantation (n = 10-11 recipients per genotype; n = 4 donors 
per genotype). (F) Gene set enrichment analysis (GSEA) showing that the Nrf2 signature is not 
significantly affected in Fh1-deficient (Fh1 KO) FL Lin−c-Kit+ cells. NES: normalized enrichment 
score; FDR: false discovery rate. (G) Western blots for Hif-1α and β-actin in c-Kit+ cells from 14.5 
dpc FLs (n = 3 per genotype). CoCl2-treated FL c-Kit+ cells were used as a positive control for Hif-
1α. Asterisks indicate nonspecific bands. (H) Total FL cellularity and total number of Lin+ cells and 
HSCs in 14.5 dpc FLs. Data are mean ± s.e.m. (Fh1fl/fl;Hif-1α+/+ n = 12, Fh1fl/fl;Hif-1α+/+;Vav-iCre 
n = 9, Fh1fl/fl;Hif-1αfl/fl n = 6, Fh1+/fl;Hif-1αfl/fl;Vav-iCre n = 5, Fh1fl/fl;Hif-1αfl/fl;Vav-iCre n = 4). (I) 
Western blot for H3K4me3, H3K9me3, H3K27me3, H3K36me3 and total H3 in 14.5 dpc FL c-Kit+ 
cells (n = 3 per genotype). (J) Quantification of the data (normalized to total H3) shown in panel I. 
Mean ± s.e.m. (K) Biological processes (presented as –log10 (P-value)) that are enriched in up-
regulated and down-regulated genes in Fh1-deficient FL Lin−c-Kit+ cells versus control cells. 
Analysis was performed using the Gene Ontology Consortium database. The dashed grey line 
indicates P = 0.05. (L) Signature enrichment plots from GSEA analyses using unfolded protein 
response, apoptosis in response to ER stress and protein translation signature gene sets. (F, K-L) 
Gene expression analysis was preformed using Lin−c-Kit+ cells from 3 Fh1fl/fl (WT) and 4 
Fh1
fl/fl;Vav-iCre (Fh1 KO) embryos. (A-E, H, J) *, P < 0.05; **, P < 0.01; ***, P< 0.001; ****, P < 
0.0001 (Mann-Whitney U test). 
 
Figure 5. Fh1 is required for leukaemic transformation. (A) 14.5 dpc FL c-Kit+ cells were 
transduced with Meis1/Hoxa9, MLL-AF9, MLL-ENL and AML1-ETO9a retroviruses and plated into 
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methylcellulose. (B) Colony counts (mean ± s.e.m.) 6 days after plating are shown. n = 4-5 per 
genotype. (C) Fh1+/+ and Fh1fl/fl (without Vav-iCre) FL LSK cells were co-transduced with Meis1 
and Hoxa9 retroviruses and serially re-plated. The cells were subsequently infected with a 
bicistronic lentivirus expressing iCre and a Venus reporter. Venus+ cells were plated into 
methylcellulose. In parallel, Fh1+/+ and Fh1fl/fl pre-leukaemic cells were transplanted into recipient 
mice. LICs (CD45.2+c-Kit+ cells) were sorted from the BM of leukaemic recipients, transduced 
with Cre lentivirus and plated into methylcellulose. (D) Number of colonies generated by Cre-
expressing pre-leukaemic cells. Data are mean ± s.e.m., n = 3 per genotype. (E) Number of colonies 
generated by Cre-expressing LICs. Data are mean ± s.e.m., n = 3 per genotype. (F) Relative levels 
of FH mRNA (normalised to ACTB) in untransduced THP-1 cells and THP-1 cells transduced with 
lentiviruses expressing scrambled shRNA (Scr shRNA) and 3 different shRNAs targeting FH (FH 
shRNA1, FH shRNA2 and FH shRNA3). Data are mean ± s.e.m., n = 3. (G) Western blot for FH 
and β-actin in THP-1 cells described in Fig. 5F. (H) Apoptosis assays performed with THP-1 cells 
transduced with lentiviruses expressing Scr shRNA, FH shRNA1 and FH shRNA3. The graph 
depicts the percentage of Annexin V+DAPI− cells in early apoptosis and Annexin V+DAPI+ in late 
apoptosis. Data are mean ± s.e.m., n = 4. (I) CFC assays with THP-1 cells expressing Scr shRNA, 
FH shRNA1 and FH shRNA3. Mean ± s.e.m., n = 5. (H-I) *, P < 0.05 (Mann-Whitney U test). 
 
Figure 6. Mitochondrial Fh1 is necessary for efficient leukaemia establishment but is not 
required for AML propagation. (A) Control, Fh1fl/fl;FHCyt (i.e. Control;FHCyt) and 
Fh1
fl/fl;FHCyt;Vav-iCre FL LSK cells were co-transduced with Meis1 and Hoxa9 retroviruses and 
serially re-plated. 100,000 c-Kit+ pre-leukaemic cells were transplanted into sub-lethally irradiated 
recipient mice. (B) CFC counts at each re-plating. Data are mean ± s.e.m., n = 6-8 per genotype. (C) 
Kaplan-Meier survival curve of primary recipient mice (n = 8-10 recipients per genotype; 4 donors 
per genotype). ***, P < 0.001 Log-rank (Mantel-Cox). (D) Control and Fh1fl/fl;FHCyt;Mx1-Cre FL 
LSK cells were co-transduced with Meis1 and Hoxa9 retroviruses and serially re-plated. The 
resultant pre-leukaemic cells were transplanted into sub-lethally irradiated recipients. Once 
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leukaemic CD45.2+ cells reached 20% in the PB of recipient mice, the recipients received 8 doses 
of pIpC. 10,000 LICs (CD45.2+c-Kit+) from primary recipients were transplanted into secondary 
recipients. (E) Kaplan-Meier survival curve of primary recipient mice. pIpC treatment was initiated 
5 weeks post transplantation (n = 5-7 recipients per genotype). (F) Percentage of CD45.2+ cells in 
BM of primary recipient mice with terminal leukaemia. Data are mean ± s.e.m., n = 5-7 recipients 
per genotype. (G) Genomic PCR assessing Fh1 deletion before pIpC (top) and after pIpC (bottom) 
treatment. fl – undeleted conditional allele; ∆ – excised allele. (H) OCR in LICs isolated from the 
BM of primary recipients treated with pIpC. OCR was assayed as described in Fig 2A. Data are 
mean ± s.e.m., n = 3-5. *, P < 0.05 (Mann-Whitney U test). (I) Kaplan-Meier survival curve of 
secondary recipients transplanted with LICs sorted from leukaemic primary recipients (n = 10 per 
genotype). (J) Representative gel showing PCR amplification of genomic DNA from the total BM 
of secondary recipients with terminal leukaemia.  
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